Skip to content
value.today
Auxogyn Inc logo

Auxogyn Inc

Formerly Auxogen Bioscience, Inc.

Total raised
$38 M
3 rounds on record
Latest round
$15 M
Jun 2016
First round on record
May 2012
Today
Went public
See the company page

Auxogyn Inc is listed today as Progyny, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Auxogyn Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2016$15 MNo. 3$10 to $50 million

Auxogyn Inc: Raise no. 3, Jun 2016

Investors in this round

9 investors had bought by the notice of Jun 29, 2016: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Auxogyn Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $20 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edwin Neumann · Executive Officer
  • Gina Bartasi · Executive Officer, Director
  • Beth Seidenberg · Director
  • Fred Cohen · Director
  • Hakan Goker · Director
  • Kathy Harris · Director
  • Linda Mintz · Director
  • Simeon George · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series B Preferred Stock; Common Stock issuable upon conversion”
  • On the use of proceeds: “Proceeds will be used for general corporate purposes including, but not limited to, executive salaries.”

Signed by Edwin Neumann, Cfo. Source: SEC Form D, newest notice filed Jun 29, 2016. Read the notice at the SEC.

equitySEC
Mar 2015$34 MIssued in a merger or acquisition$10 to $50 million

Auxogyn Inc: Private sale, Mar 2015

Investors in this round

29 investors had bought by the notice of Mar 19, 2015: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Auxogyn Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$34 M of $41 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Darrin Uecker · Executive Officer, Director
  • Gina Bartasi · Executive Officer, Director
  • Mark Weeks · Executive Officer
  • Beth Seidenberg · Director
  • Fred Cohen · Director
  • Kathryn Tunstall · Director
  • Kathy Harris · Director
  • Linda Mintz · Director
  • Nilesh Kumar · Director
  • Simeon George · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “A portion was issued in a financing and a portion was issued as consideration in an acquisition”

Signed by Gina Bartasi, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 19, 2015. Read the notice at the SEC.

equitySEC
Sep 2013$6 MNo. 2$2 to $10 million

Auxogyn Inc: Raise no. 2, Sep 2013

Investors in this round

4 investors had bought by the notice of Sep 16, 2013: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Auxogyn Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $10 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: (i) Ser B Pref Stock; Common Stock upon conversion,(ii) Pref Stock Warrant; Pref Stock upon exercise; Common Stock upon conversion, and (iii) convertible promissory notes; Pref Stock upon conversion;
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Laura Francis · Executive Officer
  • Lissa Goldenstein · Executive Officer, Director
  • Beth Seidenberg · Director
  • Kathryn Tunstall · Director
  • Mark Gudiksen · Director
  • Nilesh Kumar · Director
  • Simeon George · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount and total amount sold above both include amounts which will be received if the warrants are fully exercised.”
  • On the use of proceeds: “Proceeds will be used for general corporate purposes including, but not limited to, executive salaries.”

Signed by Lissa Goldenstein, President and CEO. Source: SEC Form D, newest notice filed Sep 16, 2013. Read the notice at the SEC.

equity, debt, optionsSEC
May 2012$18 MNo. 1$10 to $50 million

Auxogyn Inc: Raise no. 1, May 2012

Investors in this round

4 investors had bought by the notice of Jun 4, 2012: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Auxogyn Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
$1,000,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Greg Garfield · Executive Officer
  • Greg Johnstone · Executive Officer
  • Lissa Goldenstein · Executive Officer, Director
  • Beth Seidenberg · Director
  • Mark Gudiksen · Director
  • Nilesh Kumar · Director
  • Rene Reijo Pera · Director
  • Simeon George · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for general corporate purposes including, but not limited to, executive salaries.”

Signed by Lissa Goldenstein, President and CEO. Source: SEC Form D, newest notice filed Jun 4, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Progyny, Inc., its revenue in fiscal 2025 came from these product and service lines: Fertility benefit services revenue $830.93 million (64%), Pharmacy benefit services revenue $457.73 million (36%).

    Annual report (SEC XBRL) · Dec 2025

  • Auxogyn Inc chose not to state its revenue in its newest notice of a funding round (Jun 2016).

    SEC Form D · Jun 2016

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jun 2016

Products and services#

No products or services of Auxogyn Inc are on record.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Auxogyn Inc
InvestorKindAmountRoundRoleSource
GSK PLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Kleiner Perkins Caufield & Byers XIII, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KPCB XIII Associates, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
TPG Group Holdings (SBS) Advisors, Inc.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 9 investors.

Largest shareholders today

Institutions holding Progyny, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Auxogyn Inc
NameRoleNamed in
Edwin NeumannExecutive officerJun 2016
Gina BartasiExecutive officerJun 2016
Darrin UeckerExecutive officerMar 2015
Mark WeeksExecutive officerMar 2015
Laura FrancisExecutive officerSep 2013
Lissa GoldensteinExecutive officerSep 2013
Greg GarfieldExecutive officerJun 2012
Greg JohnstoneExecutive officerJun 2012
Beth SeidenbergDirectorJun 2016
Fred CohenDirectorJun 2016
Gina BartasiDirectorJun 2016
Hakan GokerDirectorJun 2016
Kathy HarrisDirectorJun 2016
Linda MintzDirectorJun 2016
Simeon GeorgeDirectorJun 2016
Darrin UeckerDirectorMar 2015
Kathryn TunstallDirectorMar 2015
Nilesh KumarDirectorMar 2015
Lissa GoldensteinDirectorSep 2013
Mark GudiksenDirectorSep 2013
Rene Reijo PeraDirectorJun 2012

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.